Omeros: H.C. Wainwright Doubles Price Target - Expert Sees 187% Upside Potential! The Transformation into a Commercial Biopharma Company

The Omeros Corporation (OMER) has made a historic turnaround in recent weeks, transforming from a research-focused biotechnology company into a fully operational commercial player. Central to this development is the focus on treating complement system disorders, a part of the immune system that, when dysregulated, can cause severe organ damage. The company sees itself as a pioneer in the targeted inhibition of the lectin pathway, for which it has developed the drug Narsoplimab, now ready for the market. From the corporation's perspective, this...